AIM ImmunoTech Inc. filings document an immuno-pharma issuer centered on Ampligen (rintatolimod) and its public-company financing, clinical and governance disclosures. Recent 8-K reports cover material agreements, Regulation FD clinical updates for the DURIPANC pancreatic cancer study, amendments to equity distribution arrangements, warrant notices, and operating and financial results.
Registration statements and related exhibits disclose rights-offering terms, Series G Convertible Preferred Stock, common stock purchase warrants, beneficial-ownership limits, warrant agency arrangements, and shelf or at-the-market equity issuance mechanics. The filings also address risk factors, shareholder-rights modifications, corporate-governance items and capital-structure changes relevant to AIM's research-and-development drug business.
AIM ImmunoTech Inc. CEO & President Thomas K. Equels purchased 20,299 shares of common stock on November 6, 2026, at $0.1560 per share. The shares were held directly, and his reported direct holdings after the purchase were 210,046 shares. The Rule 10b5-1 plan box was unchecked.
AIM ImmunoTech announced a new presentation on investigating Ampligen with RAS-targeted treatment, including daraxonrasib, for pancreatic cancer. The proposed combination remains investigational; its safety, efficacy and ability to improve outcomes beyond daraxonrasib alone have not been established. In randomized Phase 3 RASolute 302 results, daraxonrasib’s median overall survival was 13.2 months versus 6.7 months with chemotherapy, and median progression-free survival was 7.2 months versus 3.6 months.
The presentation also cites exploratory findings from a nonrandomized Netherlands Named Patient Program: 57 Ampligen-treated patients had median overall and progression-free survival of 19.7 and 12.6 months, compared with 12.5 and 8.6 months among 27 historical controls. DURIPANC evaluates Ampligen with durvalumab in 28 patients with metastatic pancreatic cancer who achieved stable disease after FOLFIRINOX. Phase 2 results for clinical benefit rate at 24 weeks are anticipated in Q1 2027; additional survival, quality-of-life and immune-response analyses are anticipated in Q3 2027.
AIM ImmunoTech Inc. CEO & President and director Thomas K. Equels reported a purchase of 31,675 common shares on October 23, 2026, at $0.16 per share; the transaction is described as an open-market or private transaction. The purchase was reported as direct ownership, and Equels directly held 189,747 shares after the purchase. No Rule 10b5-1 plan is reported for the transaction.
AIM ImmunoTech Inc. CEO & President Thomas K. Equels purchased 31,250 shares of Common Stock on October 22, 2026, at $0.163 per share. The purchase was reported as direct, and his reported direct holdings after the transaction were 158,072 shares. No Rule 10b5-1 plan is reported.
AIM ImmunoTech Inc. is seeking shareholder votes at its virtual annual meeting, scheduled for November 17, 2026, on five director nominees, the ratification of BDO USA, P.C. as its independent registered public accounting firm for fiscal 2026, and non-binding advisory approval of named executive officer compensation. The nominees are Nancy K. Bryan, David I. Chemerow, Thomas K. Equels, Ted D. Kellner and William M. Mitchell. The Board recommends voting FOR all three proposals.
Approximately 39,894,844 shares were outstanding and entitled to vote as of September 28, 2026, with one vote per share. A quorum requires holders of 33 and 1/3% of those shares to be present virtually or by proxy. BDO’s total fees were $826,650 for 2025 and $814,790 for 2024. The meeting will be held by live webcast, with preregistration required by November 16, 2026.
AIM ImmunoTech Inc. (AIM) reported that CEO and President Thomas K. Equels purchased 24,000 shares of common stock in a open market or private transaction on September 17, 2026, at $0.208 per share, bringing his directly held position to 126,822 shares.
No Rule 10b5-1 trading plan is reported for this transaction.
AIM ImmunoTech Inc. (AIM) reported that its CEO and President, Thomas K. Equels, purchased 11,000 shares of common stock on September 16, 2026, in an open-market or private transaction at $0.21 per share. Following this buy, he directly holds 102,822 common shares, and no Rule 10b5-1 trading plan is reported.
AIM ImmunoTech Inc. (AIM) reported that CEO & President Thomas K. Equels purchased 22,000 shares of its Common Stock on September 15, 2026 in a purchase described as an open market or private transaction at $0.221 per share. Following this buy, he directly owns 91,822 shares of AIM Common Stock. No Rule 10b5-1 trading plan is reported for this transaction.
AIM ImmunoTech Inc. (AIM) reported that CEO and President Thomas K. Equels purchased 5,900 shares of its Common Stock on September 14, 2026, in a purchase characterized as an open market or private transaction at $0.219 per share. Following this transaction, he holds 69,822 shares with direct ownership, and no Rule 10b5-1 trading plan is reported.